David Hofer

David Hofer, Managing Director

Answering Your Questions on Rescheduling Our take on 2024 Cannabis Strategic Investment Forecast

As you will see in the interview with Benzinga, as you scroll down below, we are bullish on the impact resched-uling will have on cannabis strategic investments this year. That view is reinforced by the article at this link:


At the same time, however, a recent article in the WSJ raises doubts about the DEA rescheduling at all. Our take is there are some old school folks in the DEA that are sending up a trial balloon in the press to see if their view will be accepted by the administration. I am quite sure the White House, Justice Department and HHS are letting the DEA Director know their thoughts and feelings on this. 🙂

Our understanding is that the DEA has to follow HHS s binding scientific and medical evaluation.” So, the DEA can choose which schedule but they can t say we disagree with HHS on the medical evaluation so we stand pat. The recent WSJ article implies the DEA can do what they want – that s incorrect. They must use HHS guidance. Now the DEA could decide to only put cannabis to schedule 2 not 3 but they can t ignore HHS outright and do nothing – not without some serious repercussions.

The fact that Biden brought up cannabis in the State-of-the-Union address elevates the risks to the DEA. If the DEA ignores HHS that would be without precedent and heads would roll and careers would end at the DEA. Anything could happen but we think the worst outcome would be schedule 2.

Another perspective on this is provided by Akin Gump, a well-respected DC law firm. They reference codes and talk about what the agencies can and can t do…


LET’s TALK – at the Benzinga
Cannabis Capital Conference.

Get the Highway EDGE on vital markets for your portfolio.

Highway 33 is a capital advisory firm capable of handling global transactions. We thrive in fiercely competitive and highly regulated industries. Including but not limited to: pharma, biotech, healthcare, cannabis, CBD/hemp and ancillary technology companies.



Markets and Research forecasts the worldwide pharmaceutical market to grow to $1.5 trillion next year. This growth is driven by global demographic and economic trends, including growing demand for more effective wellness programs and medical treatments…

Learn More


For the various investment strategies of our clients in BioTech, the segments of HealthTech and WellnessTech are particularly fertile ground. Not only is our staff well versed in the many facets of BioTech, but interest in this field has intensified with…

Learn More


Advances are AgTech are attracting stronger and stronger investor interest – with total capital funding reaching $2.7 billion invested across 289 venture financing rounds last year. Innovations in…

Learn More


The size of the global cannabis industry was USD $10 billion in 2018 and is projected by Forbes Business Insights to reach USD $97.35 billion by the end of 2026. That’s an astounding CAGR of 32.93% during that period….

Learn More
CBD Hemp


Cannabidiol (CBD) market size exceeded USD $2.8 billion in 2019 and is set to grow at the unprecedented rate of 52.7% CAGR between 2020 and 2026. Cannabidiol is a compound found in hemp plant which is being utilized for its therapeutic properties…

Learn More


In IT, SaaS companies are projected to generate $287.3 billions in revenue next year. There is a very powerful reason that has special significance for investors – since with over 80% of all enterprise workloads now shifted to the cloud. It won’t be long before companies are running solely on SaaS.

Learn More

Well-structured capital requires a solid foundation.

Highway 33 is a boutique capital advisory firm that specializes in structuring mergers and acquisitions as well as debt and equity fundraising transactions. Our skill set is unique. Our industry-domain experience is deep. We specialize in preparing and introducing well-vetted Investment opportunities to a network of high net-worth individuals, family offices, private equity firms, venture capitalists and specialty-focused funds.

We specialize. Structure capital.
And vet, vet, vet.

We excel in highly regulated industries. Structuring capital needs for clients in pharma, biotech, healthcare, cannabis, CBD/hemp and ancillary technologies. We drive growth and enterprise valuations for our clients through M&A, non-dilutive debt financing and/or capital investments ranging from $5M to $100M+. Since our industries of specialization are known for volatility and risk, we serve companies who have established clear market-leadership potential. And have “passed” our thorough vetting process.

For solutions that come from everywhere, start here.

Because we’re independent, we can offer unbiased strategic direction, delivered by a uniquely skilled team. Our areas of expertise cover virtually every aspect of business and industry – investment, operations, legal and public policy, engineering, finance, research, even marketing. And all of our experience is available, at a moment’s notice, to help you define and attain your investment objectives in the industries we know best – including the new frontier of the cannabis marketplace.

33 Icon

We exist to structure and secure capital.
For innovative industries.

Highway 33 Capital Advisory team provides the consultation and capital-structure services to build leadership brands in the biotech, pharmaceutical, health tech and cannabis industries, including in legal medical and adult-use recreational markets. Our services include the acquisition of growth and expansion capital, M&A transactions, product licensing and distribution agreements.

We know canna. We know capital.

Introducing our new Canna Debt Fund. Canna needs capital. Lack thereof is the biggest stumbling block to incredible growth since government regs. The Fund’s target return is 9.65% annually to investors. Our primary market focus is cannabis, hemp/CBD, biomass purchases for extractors, and financing commercial real estate, equipment and short-term working capital needs of licensed growers, extractors and retailers. Interested?

Industry insights to give you an edge.

Trends. Who’s investing where. Why. And what’s next. Keep up to date with changing times and changing markets. Be ahead of the curve. Get the Edge by subscribing to our weekly newsletter featuring industry viewpoints and unique investment opportunities: